Investment Banking
Biotech industry publication EndPoints cited William Blair investment banking’s “Quarterly Rx” report for its story on the current state of life sciences sector IPOs.
Among the factors impacting IPOs for life sciences companies, the report cited by EndPoints notes, is an increase in the time between the crossover funding round and an IPO, and the increased gap between the series B and series C funding rounds on average.
Stay up-to-date with the latest William Blair news and insights
William Blair acted as the exclusive financial advisor to Duomed Group, a portfolio company of G Square Healthcare Private Equity, in connection with the contemplated sale to Palex Medical, a portfolio company of Apax Partners and Fremman Capital.
Read moreThe 220,000+ companies that contract with the Department of Defense will soon face a significantly expanded regulatory framework—known as CMMC 2.0—designed to thwart increased cyber threats and secure the defense industrial base.
Read moreWilliam Blair acted as the exclusive financial advisor to TT medic GmbH and its shareholders in connection with entering a partnership with Trill Impact.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
